NCT06339008

A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/ LY3650150 in Adult Participants With Perennial Allergic Rhinitis

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 450 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. Participants can expect study participation to last up to 29.5 months.

Conditions

• Perennial Allergic Rhinitis (PAR)

Interventions

Type	Name	Description
DRUG	LY3650150	Administered SC
DRUG	Placebo	Administered SC
DRUG	Standard therapy for INCS	Administered as intranasal spray

Timeline

• Start date: 2024-04-26
• Primary completion: 2026-09-01
• Completion: 2028-10-01
• First posted: 2024-04-01
• Last updated: 2026-03-24

Locations

70 sites across 6 countries: United States, Belgium, China, Germany, Poland, South Korea

Regulatory

• FDA-regulated drug study